More tools:
Markets
·
Screener
·
Research
·
Chat
Eikon Therapeutics, Inc. Common Stock (EIKN) Financial Statements
Eikon Therapeutics, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00T0XRJ84
XNAS · usd
10.71
▼ 0.15 (-1.38%)
As of 2026-09-08
1M
6M
1Y
Valuation
Market Cap
$580.1M
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
10.86
Day's Range
10.61 – 11.03
52-Week Range
7.90 – 17.40
Volume
449.7K
Avg Volume
431.2K
Share Statistics
Shares Outstanding
54.2M
Employees
384
Exchange
XNAS
Listed
2026-02-05
Share count as of August 3, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about Eikon Therapeutics, Inc. Common Stock (EIKN)
What is Eikon Therapeutics, Inc. Common Stock's Market Cap?
Eikon Therapeutics, Inc. Common Stock's Market Cap is $580.1M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Operating expenses:
Research and development
75,460.0
70,047.0
General and administrative
17,934.0
17,290.0
Total operating expenses
93,394.0
87,337.0
Loss from operations
(93,394.0)
(87,337.0)
Interest income (expense), net
5,037.0
4,380.0
Other income (expense), net
(52.0)
(1.0)
Net loss and comprehensive loss
(88,409.0)
(82,958.0)
Net loss attributable to common stockholders
(88,409.0)
(82,958.0)
Net loss per share attributable to common stockholders, basic
(1.63)
(2.46)
Net loss per share attributable to common stockholders, diluted
(1.63)
(2.46)